Ambry
Investigators embraced recently developed computational tools, with guidance from experts, to assess whether protein structure data can help predict the effects of gene variants.
In Brief This Week: Tempus AI, Myriad Genetics, 23andMe, DNAnexus, Dovetail Genomics
News items for the week of Feb. 3, 2025.
TD Cowen Reinstates Buy Rating for Tempus AI, Raises Price Target to $74
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.
BRCA2 Variants Classified in Saturation Genome Editing Studies
Research teams relied on CRISPR-Cas9-based editing and sequencing to perform high-throughput function evaluations of loss-of-function variants in exons 15 to 26 of BRCA2.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.